Literature DB >> 1354446

Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.

S K Kundu1, T C Merigan.   

Abstract

OBJECTIVES: Cytotoxic T-lymphocytes (CTL) appear to be an important defense mechanism against HIV infection. This study proposes to examine the major histocompatibility complex (MHC)-restricted HIV-1 Env-, Gag- and Pol-specific CTL activities in HIV-infected asymptomatic patients.
DESIGN: CD4+ and CD8+ CTL were examined to establish whether the same HIV-1 protein (Env, Gag or Pol) was recognized by both CD4+ and CD8+ CTL with MHC antigen restriction.
METHODS: Peripheral blood mononuclear cells, CD4+ and CD8+ T-cells from 17 HIV-infected asymptomatic patients and 10 HIV-seronegative individuals were examined for HIV-1 Env-, Gag- and Pol-specific MHC-restricted cytotoxicity using autologous and heterologous B-lymphoblastoid cell lines infected with vaccinia recombinant expressing HIV-1 Env, Gag and Pol proteins as targets.
RESULTS: CD4+ and CD8+ CTL specific for the HIV-1 Env, Gag and Pol were demonstrated in the peripheral blood. DR4 and DQw2 were possible sites of MHC class II restriction of CD4+ CTL. Possible MHC class I restriction sites of CD8+ CTL included A2 and B8 for Env, A1 and A2 for Gag, and A2 and B8 for Pol antigen.
CONCLUSIONS: These observations should help to define more precisely the nature and elements of protective immunity and to evaluate AIDS vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354446

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Heterogeneity of cytokine functions in HIV infection.

Authors:  S K Kundu; T C Merigan
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 2.  Immunopathology of human immunodeficiency virus infection in the gastrointestinal tract.

Authors:  T Schneider; R Ullrich; M Zeitz
Journal:  Springer Semin Immunopathol       Date:  1997

3.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones.

Authors:  P J Norris; M Sumaroka; C Brander; H F Moffett; S L Boswell; T Nguyen; Y Sykulev; B D Walker; E S Rosenberg
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 5.  Cytolytic CD4(+) T cells in viral immunity.

Authors:  Damien Z Soghoian; Hendrik Streeck
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

Review 6.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

7.  Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells.

Authors:  Philip J Norris; Howell F Moffett; Otto O Yang; Daniel E Kaufmann; Margaret J Clark; Marylyn M Addo; Eric S Rosenberg
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes.

Authors:  Z Smit-McBride; J J Mattapallil; M McChesney; D Ferrick; S Dandekar
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina.

Authors:  S J Kent; L Corey; M B Agy; W R Morton; M J McElrath; P D Greenberg
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.

Authors:  S K Kundu; D Katzenstein; L E Moses; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.